{
    "clinical_study": {
        "@rank": "67050", 
        "arm_group": [
            {
                "arm_group_label": "AZD3293", 
                "arm_group_type": "Experimental", 
                "description": "Part 1: Up to 6 sequential cohorts of healthy elderly subjects are planned, with multiple ascending doses, starting with 5 mg (subject to confirmation by the Safety Review Committee) Part 2: Up to 16 mild-to-moderate AD patients administered one to up to 3 dosage levels of AZD3293"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Part 1:  Placebo given (2 subjects in each cohort) Part 2:  Placebo given (up to 4 subjects)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a two-part multiple dose study in healthy male and female (of non-child bearing\n      potential) elderly volunteers, and in Alzheimer's disease patients, to assess the safety,\n      effects on the body, and blood, CSF, and urine drug levels of AZD3293.  AZD3293 is being\n      developed for the treatment of Alzheimer's Disease"
        }, 
        "brief_title": "A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Elderly Volunteers", 
            "Mild-to-moderate Alzheimer's Disease Patients"
        ], 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "detailed_description": {
            "textblock": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose\n      Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of\n      AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly\n      Volunteers and in Mild-to-Moderate Alzheimer Disease Patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Part 1:  Healthy elderly male and female (of non-childbearing potential) subjects.\n\n          -  Part 2:  Male and non-fertile female AD patients.\n\n          -  Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more\n             than 100 kg.\n\n          -  Part 2:  Clinical diagnosis of probable AD according to the NINCDS-ADRDA criteria.\n\n          -  Part 2:  Manifestation of AD symptoms at least 6 months before randomization.\n\n        Exclusion Criteria:\n\n          -  Part 1: History or presence of psychiatric disease/condition, GI, renal, hepatic,\n             cardiovascular, psychiatric, or retinal diseases or disorders.\n\n          -  Part 2:  Significant disease affecting the CNS other than Alzheimer's disease,\n             including but not limited to other dementias, other significant neurological or major\n             psychiatric disease.\n\n          -  History of use of antipsychotic drugs , or chronic use of antidepressant or\n             anxiolytic drugs.\n\n          -  Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other\n             nicotine products.\n\n          -  History of neurological disease, including seizures, recent memory impairment, or\n             clinically significant head injury."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795339", 
            "org_study_id": "D5010C00002"
        }, 
        "intervention": [
            {
                "arm_group_label": "AZD3293", 
                "description": "Oral solution", 
                "intervention_name": "AZD3293", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Oral solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "AZD3293", 
            "Healthy volunteers", 
            "Elderly volunteers", 
            "Alzheimer's Disease patients", 
            "AD patients", 
            "Phase 1", 
            "Multiple Ascending Dose Study"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly Volunteers and in Mild-to-Moderate Alzheimer Disease Patients", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Robert C Alexander, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "PAREXEL/CCT Early Phase Clinical Unit", 
                "last_name": "David Han, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Adverse event monitoring", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline up to 20 days"
            }, 
            {
                "measure": "Assessment of vital signs (blood pressure, pulse and body temperature) and physical exams", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline up to 20 days"
            }, 
            {
                "measure": "Clinical laboratory tests (chemistry, hematology, urinalysis, renal safety)", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline up to 20 days"
            }, 
            {
                "measure": "Assessment of 12-lead digital electrocardiograms to measure rhythm, rate, morphology, QT/QTc interval", 
                "safety_issue": "Yes", 
                "time_frame": "Fron Baseline up to 20 days"
            }, 
            {
                "description": "Columbia-Suicide Severity Rating Scale (C-SSRS) captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. Some questions are yes/no and some are on a scale of 1 (low severity) to 5 (high severity). Completed suicide and non-fatal suicide events are yes/no questions and results presented are the number of participants with these events. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.", 
                "measure": "Assessment of telemetry, as reported by Investigator Columbia-Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline up to 20 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795339"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Investigation of the effect of AZD3293 on plasma and cerebrospinal fluid (CSF) biomarkers relevant for Alzheimer Disease (AD)", 
                "safety_issue": "No", 
                "time_frame": "Up to 17 days"
            }, 
            {
                "measure": "Investigation of the effect of AZD3293 on plasma and cerebrospinal fluid (CSF) biomarkers relevant for Alzheimer Disease (AD) in mild-moderate AD patients in comparison to elderly healthy volunteers", 
                "safety_issue": "No", 
                "time_frame": "Up to 17 days"
            }, 
            {
                "measure": "Investigation of the multiple dose Pharmacokinetics for AZD3293 and its metabolite AZ13569724, including dose proportionality for AZD3293 following oral administration", 
                "safety_issue": "No", 
                "time_frame": "Up 17 days"
            }, 
            {
                "measure": "Investigation of the Pharmacokinetics/Pharmacodynamics relationship of the effect of AZD3293 on biomarkers relevant for Alzheimer Disease (AD) in plasma", 
                "safety_issue": "No", 
                "time_frame": "Up to 17 days"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}